Esophageal carcinoma is one of the most common and highly aggressive malignant neoplasms in the world, particularly in China. More than 90% of esophageal cancers are ESCC.
Esophageal carcinoma is one of the most common and highly aggressive malignant neoplasms in the world, particularly in China. More than 90% of esophageal cancers are ESCC. 1, 2) Despite advances made in surgical techniques and chemo-radiotherapy during the past several decades for the treatment of ESCC, the prognosis of ESCC remains poor with the 5-year survival rate of approximately 15%. 2, 3) Moreover, unresectable and relapsed esophageal cancers are still resistant to the currently available chemotherapy or radiotherapy regimens, and there is no substantial change in overall survival. The poor prognosis of esophageal cancer is due to the lack of early screening strategies, and most of patients are in advanced stage at diagnosis. As a result, its mortality rate is almost equal to its incidence in some countries.
2) Consequently, there is an urgent need to develop a novel therapeutic strategy for this disease, and immunotherapy may be a promising approach for improvement of ESCC treatment. However, the tumor associated antigens that can be used as vaccine for successful ESCC immunotherapy have not been well identified, and it has been suggested that the HPV16 E7 protein could be a potential target for ESCC vaccine. 4) Epidemiological studies indicate that many factors may be associated with esophageal cancer. However, the molecular mechanisms of ESCC still remain unclear.
3) Accumulating evidence has also suggested that infection with high-risk HPVs, particularly HPV type 16, has been reported as a potential risk factor for ESCC, especially at high incidence areas in China. 3, [5] [6] [7] The E6 and E7 oncoproteins of the highrisk HPV types can efficiently destroyed the cell cycle regulatory machinery and the apoptotic pathways by binding to a number of host-cell proteins. 8) Thus, the ability of HPV oncoproteins to alter control of the cell cycle imparts growth advantage on the cells and leaves them vulnerable to other genetic changes that ultimately result in malignant transformation. Therefore, the consistent expression of E6 and E7 oncoproteins with strong immunogenicity in HPV-containing precancerous lesions and carcinomas suggests that these proteins represent attractive targets for immunotherapeutic strategies against HPV-associated malignancies. 8) Additionally, circulating HPV E7 specific effector T cells were detectable in patients with squamous cell carcinoma of the oropharynx (SCCO) and in squamous cell carcinoma of the head and neck (SCCHN) patients. 9, 10) Indeed, the malignant transformation of human esophageal epithelial cells was also induced in vitro by high-risk E6/E7 in synergy with TPA or human telomerase reverse transcriptase (hTERT), and these cells showed many features similar to those of ESCC. 11, 12) These observations supported the role of HPV in esophageal carcinogenesis. Therefore, the immunogenicity of HPV 16 E7-encoded antigen might be critical factors to developing vaccine-based strategies for enhancing antitumor immunity in patients with HPV16 E7-expressing ESCC. However, there were few reports on successfully experimental vaccination using the HPV 16 E7-encoded antigen as cancer-specific immunotherapy for this disease.
So far, the immunogenicity of anti-HPV vaccines and their antitumor efficacy have been evaluated in vivo by using TC-1 cell line and C57BL/6 mouse model which mainly generated immune responses to the HPV16-E6/E7 H-2Db-restricted epitope. 13, 14) Yet, the conclusions drawn from these animal models are incomplete in reflection of the interaction between human immune system and HPVs vaccines. Consequently, it is indispensable to develop a small animal model in which human lymphocytes, particularly human CD4 ϩ /CD8 ϩ T cells, can be engrafted in an in vivo environment to mimic the human immune system and induce specific antitumor immunity. The Hu-PBL-SCID mouse model, produced by engrafting the immunocompetent human peripheral blood lymphocytes (HuPBLs) into SCID mice, is an ideal animal system designed to study the human immune responses to vaccination 15, 16) and cancer immunotherapy. 17) Since this animal model was originally reported by Mosier et al. in 1988, 18) numerous reports have demonstrated that the coengraftment of tumor cells and HuPBLs donated by healthy adult volunteers into SCID mice provides the opportunity to evaluate anti-tumor immune response of human lymphocytes that is more clinically relevant. This animal model has been successfully applied to evaluate the BCGbased vaccine breast cancer vaccine, 19) the DC-based vaccine against human hepatocarcinoma cells 20) and the anti-tumor efficacy against a wide spectrum of human tumors including lymphoma, glioblastoma, head and neck squamous cell carcinoma, lung and ovarian cancer using cytokine-based immunotherapies 17, [21] [22] [23] [24] [25] In the majority of these studies, the HuPBLs were allogeneic with respect to the tumor and the allo-anti-tumor response was found to be mediated primarily by CD8
ϩ T-and CD56 ϩ NK-cells without HLA typing. 19, 22, 23, 25) These observations suggest that utilizing the Hu-PBL-SCID mouse model for evaluation of cancer vaccine is quite feasible.
We have successfully fused the truncated Mycobacterium tuberculosis heat shock protein 70 (TBhsp70) with HPV-16 mE6D/mE7 to generate a recombinant fusion protein as an adjuvant-free vaccine, HPV16 mE6D/mE7/TBhsp70D, and demonstrated that the fusion protein vaccine or the mE6D/mE7 protein plus IFA induced anti-tumor immunity against TC-1 tumor cells in C57BL/6 mouse model. 26, 27) In the present study, we further evaluated the protective activity of this vaccine against HPV16 E7-expressing human ESCC cell challenge in a Hu-PBL-SCID mouse model. We showed that modulation of the tumor microenvironment by HPV16 mE6D/mE7/TBhsp70D fusion protein vaccine can induce tumor cells to undergo apoptosis, and result in the inhibition of tumor growth in Hu-PBL-SCID mice.
MATERIALS AND METHODS

Cell Lines and Animals
The ESCC cell line EC9706 and an HPV 16-negative cell line, EC/CUHK1, were described previously, 28, 29) respectively. The HPV16-E7 positive CaSki cervical carcinoma cell line was from American Type Culture Collection (ATCC). The ESCC and CaSki cells were maintained in RPMI 1640 medium (Gibco-BRL), and the EC/CUHK1 cells were grown in DMEM medium (Gibco-BRL). Both media were supplemented with antibiotics (100 IU/ml penicillin and 100 mg/ml streptomycin) and 10% (v/v) heat inactivated fetal calf serum (FCS) (HyClone). Cells were cultured at 37°C in 5% CO 2 humidified incubator. SCID mice were obtained from the Experimental Animal Center of Peking Union Medical College (PUMC) and kept under specific pathogen-free (SPF) conditions. All experiments were undertaken in accordance with ethical guidelines for care and use of laboratory animals at PUMC.
Reconstitution of Hu-PBL-SCID Mice, Immunization and Tumor Cell Challenge Details of the reconstitution of Hu-PBL-SCID mice were as described by others. 18, 19, 30) The vaccine and control proteins used in this study included HPV16 mE6D/mE7/TBhsp70D, HPV16 mE6D/mE7, TBhsp70D (control) and PBS (sham vaccine as negative control) were prepared as previously described. 26, 27) Fourteen days after lymphocyte reconstitution, proteins of 2.0 nM were diluted in a total volume of 200 ml of PBS or PBS alone were injected s.c. into the Hu-PBL-SCID mice in the groin of the hind leg (nϭ8), respectively. All the mice were boosted 10 d later from the first immunization with the same dose. Then, one week after the last vaccination, 3ϫ10 5 EC9706 cells or 1ϫ10 6 CaSki cells (E7-positive control) or 3ϫ10 5 EC/ CUHK1 cells (E7-negative control) were injected s.c into the right flank of mice. Following the tumor cell challenge, tumor development in mice was monitored twice weekly. Tumor growth was monitored by measuring maximal and minimal diameters by a caliper, and tumor volumes were calculated according to: (lengthϫwidth 2 )/2.
31)
Histological Analysis and Immunohistochemistry
Tumor-bearing mice were sacrificed by a deep anaesthesia when the control mice became moribund. Tumor tissues recovered from each group were fixed in 10% neutral buffered formalin, and embedded in paraffin. Sections 4 mm thick were cut, and then were carried out standard H&E staining or immunohistochemical staining with mAb specific for human CD8 using a standard Non-Biotin HRP Detection system (Zymed Corporation, San Francisco, California, U.S.A.) following the manufacturer's instructions.
Detection of Tumor Apoptosis
To detect apoptotic cells in tumor section from tumor-bearing SCID mice, TUNEL assay was performed using the DeadEnd Colorimetric Apoptosis Detection System Kit (Promega, Madison, WI, U.S.A.) follow by the manufacturer's instructions and as described previously. 32) Apoptotic cells were identified using light microscope. Cells exhibiting nuclear staining without cytoplasmic background were regarded as undergoing apoptosis. Apoptotic index (AI) was randomly estimated in 10 highpower fields (1000 total cells) and the percentage of apoptotic cells were determined as follows: apoptotic cells/total number of cellsϫ100.
Antibodies and Western Blotting Cancer cells and fresh tumor tissues recovered from the animal model were rinsed three times with cold PBS and lysed with lysis buffer, then Western blot was performed using standard immunoblotting protocols and as described elsewhere. 19) The following antibodies were used in the experiments: HPV 16 E7 (Cat #: sc-1597), Actin (Cat #: sc-7210), g-Tubulin (Cat #: sc-17788), Granzyme B(Cat #: sc-1968), Perforin (Cat #: sc-9105), INF-g (Cat #: sc-1377), TNF-a (Cat #: sc-8301), Caspase-3 (Cat #: sc-7272) and PARP (Cat #: sc-8007). These antibodies were commercially provided from Santa Cruz Biotechnology (Santa Cruz, CA, U.S.A.). All experiments were repeated in triplicate.
Cytotoxic Assay Hu-PBL-SCID mice were immunized and boosted as above described. Then, mouse spleens from each experimental groups (three per group) were disrupted, connective tissue and debris were allowed to settle, and the single cell suspensions were washed twice in RPMI 1640 medium. Human lymphocytes were enriched by Ficoll density gradient centrifugation and used as effector cells in a non-radioactive cytolytic analysis using a CytoTox 96 ® NonRadioactive Cytotoxicity Assay kit (Promega, Madison, WI, U.S.A.) according to the manufacturer's instructions and as described previously. 26, 27) EC9706, EC/CUHK1 and Caski tumor cells were used as target cells, respectively. The assay was repeated twice with similar results.
Statistical Analysis Tumor volume and results of CTL assay were expressed as meanϮS.E. of each independent experiment. One-way ANOVA was used for the comparison among three or more groups at individual time points. Tukey's HSD was used for the post-test of ANOVA using SPSS 12.0 software. Differences were considered statistically significant when the p value was Ͻ0.05.
RESULTS
Expression of the HPV16 E7 Protein in Human ESCC Cell Lines
In order to determine the expression levels of the HPV16 E7 protein in the cell lines for this study. ESCC cell lines and the cervical cancer cell line, CaSki, were examined for HPV16 E7 protein expression using Western blot. As shown in Fig. 1 , high level of HPV16-E7 protein is expressed in EC9706 and CaSki cells, whereas E7 protein was undetectable in the EC/CUHK1 cells. The in vivo growth kinetics and the concentration of these three cancer cell lines were determined in a primary experiment before embarking on the vaccine experiments, and the suitable concentration of tumor cells was 3ϫ10 5 (EC9706), 1ϫ10 6 (CaSki) and 3ϫ10 5 (EC/CUHK1), respectively. Thus, EC9706, CaSki and EC/CUHK1 tumor cells were chosen for this study as test, positive and negative control cells, respectively. The HPV16 mE6D D/mE7/TBhsp70D D Fusion Protein Vaccine Induced Anti-tumor Response against the Challenge of HPV16 E7-Expressing Human ESCC Cells in Hu-PBL-SCID Mice To confirm whether HPV16 mE6DmE7/TBhsp70D fusion protein vaccine could induce anti-tumor immune response against HPV16 E7-expressing human ESCC in Hu-PBL-SCID mice, the fusion protein vaccine immunized-mice (nϭ8) were challenged s.c. in the right flank with 3ϫ10 5 EC9706 tumor cells. As indicated in Fig. 2A , all mice immunized with the HPV16 mE6D/mE7 or PBS developed a palpable tumor with a median time to tumor detection of 9 d after the inoculation of the tumor cells. Whereas 25% mice immunized with the HPV16 mE6D/mE7/TBhsp70D fusion protein vaccine were still remained tumor-free by the end of the observation period (42 d). The median time for gross tumor detection in vaccinated-mice was 16 d (pϽ0.01). In addition, tumor xenografts in the control groups (HPV16 mE6D/mE7, PBS) showed a continual increase in size with time. The tumor growth curves for these two groups were essentially identical ( Fig.  2A) . However, the growth rate of tumors in the animals immunized with HPV16 mE6D/mE7/TBhsp70D was much slower than that observed in the control groups. On day 42, average tumor volumes in HPV16 mE6D/mE7/TBhsp70D, HPV16 mE6D/mE7 and PBS-treated mice were 261.58Ϯ 75.71, 856.73Ϯ153.51 and 858.5Ϯ113.91 mm 3 (pϽ0.01), respectively. These results suggest that the adjuvant-free vaccine, HPV16 mE6D/mE7/TBhsp70D, is capable of protecting against HPV16 E7-expressing ESCC cell challenge. However, TBhsp70D and mE6D/mE7 protein mixture or TBhsp70D alone have no prophylactic effect on the E7-expressing ESCC cell challenge (data not shown), these results were also supported by our and other studies. 26, 31, 33) The HPV-16 E7-expressing CaSki and E7-negative tumor cell line, EC/CUHK1, were employed as positive and nega- tive control, respectively. The Hu-PBL-SCID mice were challenged with 1ϫ10 6 CaSki cancer cells or 3ϫ10 5 EC/CUHK1 cells. As expected, mice immunized with the fusion protein vaccine showed significantly protective effect against the CaSki cancer cell challenge (Fig. 2B, pϽ0.01 ), but no noticeable effect was observed for the EC/CUHK1, an HPV16 E7-negative tumor cells (Fig. 2C ), indicating that in EC/CUHK1 cells there is no suitable antigen which could prime the allogeneic HuPBLs in the SCID mice, and could not elicit sufficiently immune responses against EC/CUHK1 tumors, since the tumor growth rate in the three negativecontrol groups are similar. Therefore, These results demonstrated that immunization with the HPV16 mE6D/mE7/ TBhsp70D, an adjuvant-free protein vaccine, is able to induce anti-HPV16 E7-positive tumor immunity.
Infiltration of CD8
؉ T Lymphocytes into the Tumor Site In order to further investigate the mechanisms underlying the anti-tumor effects of the vaccine, we analyzed the infiltration of CD8 ϩ T-cells in the tumor microenvironment using H&E stain and immunohistochemical analysis, respectively. As illustrated in Fig. 3 , a greater number of infiltrating lymphocytes and human CD8 ϩ lymphocytes were observed in the tumors obtained from animals treated with HPV16 mE6D/mE7/TBhsp70D (Fig. 4a, d ) compared with controltreated mice (Fig. 3b, e, and 3c, f ) .
Enhancement of Apoptosis in Tumor Xenograft in Animals Immunized with the HPV16 mE6D D/mE7/TBhsp70D D Fusion Protein Vaccine To test whether the fusion protein vaccine treatment could enhance CD8
ϩ T-cell anti-tumor function by inducing apoptosis in the tumor site, tumor tissues from experimental animals were subject to TUNEL assay. As shown in Fig. 3 , much more apoptotic tumor cells were observed in the tumor sections from vaccinated-animals ( Fig. 3g) compared with the tumors from control groups (Fig. 3h, i) . The AI in the experimental group was higher than that in the two control counterparts (pϽ0.001) (Fig. 3) . To confirm the results, immunoblotting analysis revealed that the activation of capase-3 and the product of a Mr 85000 fragment (cleaved fragment) of poly (ADP-ribose) polymerase (PARP, Mr 116000), were markedly increased in the lysate of tumor tissues from the fusion protein vaccine treated mice (Fig. 4A) .
Up-Regulation of IFN-g g, TNF-a a, Granzyme B and Perforin Protein Levels in the Tumors Derived from Mice
Immunized with the HPV16 mE6D D/mE7/TBhsp70D D Fusion Protein Vaccine Granzyme B and perforin are two downstream factors critical for CD8
ϩ T-cell function, while IFN-g and TNF-a are important cytokines involved in tumor cell apoptotic pathway, and also these cytokines are the markers for T-cell activation. 34) To investigate whether these cytokines are involved in the anti-tumor effects in the vaccinated-mice, immunoblotting analysis was performed to evaluate the expression levels of IFN-g, TNF-a, granzyme B and perforin in fresh tumor tissues from mice vaccinated by either the fusion protein vaccine or the HPV16 mE6D/mE7 or 
. Detection and Characterization of Tumor-Infilitrating Lymphocytes and Apoptosis in Tumors
Tumor tissues obtained from mice immunized with HPV16 mE6D/mE7/TBhsp70D, HPV16 mE6D/mE7 and PBS were stained for the presence of CD8 ϩ tumor-infiltrating lymphocytes. Tumor-infiltrating CD8 ϩ T cells were mainly detected in tumors obtained from animals vaccinated with HPV16 mE6D/mE7/TBhsp70D (a, d). TUNEL assay revealed that most tumor cells in the tumor sections from mice immunized with the fusion protein vaccine (g) were undergone apoptosis compared with control groups (h, i). The AI in the experimental group was higher than that in the two control counterparts ( * pϽ0.001). PBS. As expected, significantly high levels of granzyme B (32 kDa) and TNF-a (17 kDa) were detected in the tumor lysates from mice vaccinated by the fusion protein vaccine (Fig. 4B) , although slight signals of the two cytokines were also observed in the tumor lysates obtained from the control groups. Observably enhanced levels of perforin (70 kDa) and IFN-g (25 kDa) were detected only in the tumor tissues from vacinated mice relative to the control groups.
Specific CTL Response Induced by Immunization with the HPV16 mE6D D/mE7/TBhsp70D D Protein Vaccine To determine whether HPV16 mE6D/mE7/TBhsp70D fusion protein vaccine may elicit specific cytotoxicity activity in Hu-PBL-SCID mice, spleen cells isolated from animals of each experimental groups (three per group) were collected as effctor cells for CTL assay. As shown in Fig. 5 , splenocytes from mice treated with HPV16mE6D/mE7/TBhsp70D protein exhibited a significant increase in tumor lysate of EC9706 and CaSki cancer cells compared with HPV16 mE6D/mE7 or PBS-treated counterparts (pϽ0.01; Fig. 5 ). Most importantly, this cytolytic activity seems to be more specific for HPV16 E7-expressing target cells (EC9706, CaSki), not for E7-negative cells (EC/CUHK1) (pϽ0.01; Fig. 5 ). These results demonstrated that the HPV16 mE6D/mE7/TBhsp70D fusion protein vaccine was able to effectively stimulate the generation of HPV16 E6/E7-specific CTL response to HPV16-positive esophageal cancer and cervical cancer cells.
DISCUSSION
The goal of this study, using Hu-PBL-SCID mice engrafted with the human ESCC cells and allogeneic PBLs, was to evaluate the anti-tumor activity of the HPV16 mE6D/mE7/TBhsp70Dfusion protein vaccine against HPV16 E7-expressing ESCC cells. SCID mice are profoundly leaking in functional, mature T and B lymphocytes, and it has been demonstrated that these animals readily accept xenograft, leading to the development of the SCID-human mouse. As these animals also readily accept graft of both human lymphocytes to create human PBL-SCID and human tumor cells, engraftment of both these populations to the same animal provides an in vivo model for analyzing immune effector mechanisms active against human malignant disease. The PBLs used to reconstitute Hu-PBL-SCID can be autologous or allogeneic, 17, 18, [21] [22] [23] [24] [25] although extension of these allogeneic studies to an autologous system is critical.
It has well been documented that the hsp70 or hsp70D must be linked to a suitable antigen to serve as a adjuvant and thereafter to induce anti-tumor responses in vivo, hsp70 or hsp70D alone or antigen alone, even the mixture of hsp70 with E7 or hsp70D with mE6D/mE7 can not induce noticeable immune responses. 26, 27, 31, 33, 35) The protein-based vaccine was designed with the following distinctive features and advantages. 26, 27) First, it contains full-length E7 and the 120 Nterminus amino acids of E6 with point-mutations for eliminating its transformation potential and enhancing its immunogenicity, 27) and this N-terminus region contains all the possible antigenic peptides/epitopes idendified so far. 26) Obviously, this full-length recombinant protein may have the advantage that it should potentially include the full range of epitopes for E6/E7 specific CD8 ϩ T cells. In addition, it is likely that full-length protein vaccination leads to presentation of epitopes in the context of various HLA alleles, and therefore it should be applicable to any patient regardless of HLA restriction. 27, 36) On the other hand, the truncated TBhsp70 was covalently linked to the E6/E7 protein as an adjuvant and coexpressed as a fusion protein. This fusion protein strategy has shown to be simple, feasible, steady and successful for administration. 26, [37] [38] [39] [40] In vivo tumor studies demonstrated that the ESCC tumor xenograft in HPV16 mE6D/mE7/TBhsp70D-immunized mice grew significantly slower than that observed in animals immunized with HPV16 mE6D/mE7 alone or PBS. The tumor size detected in the vaccinated animals was also much smaller than the tumors in the control groups. In contrast, all mice receiving the HPV16 mE6D/mE7 or PBS developed a highly aggressive tumor with a continual increase in size with time. Notably, 25% mice immunized with the fusion protein vaccine were still remained tumor-free by the end of the experiment (42 d). Similar results were also observed using an HPV16 E7-expressing cervical cancer cell line, CaSki, as positive control, but not found in animals inoculated by HPV16 E7-negative cells, EC/CUHK1. These findings suggested that unprimed HuPBLs in SCID mice exhibited no significantly inhibitory effect on the growth of the ESCC tumor xenograft. However, the adjuvant-free vaccine, HPV16mE6D/mE7/TBhsp70D, is able to induce antigen-specific immune response resulting in the selective elimination of E7-positive ESCC and the cervical cancer cells in Hu-PBL-SCID mice. In accordance with these findings, it has been recently reported by Chung and colleagues that immunization with a BCG-MUC1-based breast cancer vaccine can induce anti-tumor immune response and cause inhibition of breast tumor xenograft in Hu-PBL-SCID mice which reconstituted by HuPBLs from normal donors. This allo-antitumor response was primarily mediated by CD8 ϩ T cells regardless of HLA restriction. 19) Our findings also supported by other reports that vaccination with a DC-based vaccine has an inhibitory effects on the growth of human hepatocarcinoma in SCID mice. 20) Thereby, together with other reports, [21] [22] [23] 25) our data shown here support the notion that hu-PBL-SCID mouse model is an in vivo animal system prior to evaluate human immune responses to a range of prophylactic or therapeutic vaccine candidates for cancer immunotherapy. This study, to the best of our knowledge, is the first to demonstrate that the HPV16 mE6D/mE7/TBhsp70D fusion protein-based vaccine is capable of inducing strong immune responses to human esophageal carcinomas in Hu-PBL-SCID mouse model.
Consistent with the inhibition of tumor growth in vivo, the presence of CD 8ϩ T-cells were mainly detected in the tumors from animals immunized with the fusion protein vaccine. Also, comparison of the specific-CTL responses from splenocytes of vaccinated mice and the control groups demonstrates that vaccination with the HPV16 mE6D/mE7/TBhsp70D protein results in far better responses (Fig. 5) . Furthermore, much more tumor cells in these tumors were undergone apoptosis (Fig. 3g ) compared with the tumors from control groups (Fig. 3h, 3i ). With these findings, our data further demonstrated that the activated form of caspase-3 and the production of cleaved PARP were markedly increased in the lysates of tumors from the fusion protein vaccinated mice (Fig. 4A) . These results suggested that the apoptotic cascade was triggered and the downstream effector caspases were activated when the activated CD8
ϩ T-cells infiltrated into the tumor site, and these observations are also supported by recent findings that the protective or therapeutic effect of HPV16 E7/TBhsp70 fusion protein or DNA vaccine using E7 gene linked to TBhsp70 gene against E7 expression tumors was mainly dependent on CD8 ϩ T-cell responses and by-passing CD4 ϩ T-cell responses. 31, 33, 35) This adjuvanticity of TBhsp70 is most likely due to its ability to activate dendritic cells (DCs) via specifically binding to CD40 or CD91 expressed on DCs and macrophages surface, consequently resulting in specific activation of naive CD8 ϩ T cells. [41] [42] [43] In addition, binding TBhsp70 to CD40 could induce human monocyte-derived DCs to produce CC chemokines which facilitate the actived immune cells to traffic into the tumor site. 44) Importantly, experiments performed by others have also revealed that fusion proteins containing TBhsp70 and Ag sequences facilitate MHC-I cross-presentation of linked antigenic epitopes. 42, 45) These findings provided convincing evidence on the adjuvant effect of the TBhsp70 protein that play crucial role in direct activation of the host immune system. Hence, it is tempting to speculate that TBhsp70D used in our current vaccine-design might use similar mechanisms to achieve potent CTL activity by-passing CD4 ϩ T-cell responses to E6/E7 antigen.
In our present study, the up-regulation of several immunemediator cytokines, including IFN-g, TNF-a, granzyme B and perforin, in the tumors from the fusion protein vaccinated-mice was observed (Fig. 4B) . IFN-g is an important cytokine for cancer therapy, and it is also a key marker for Tcell activation. 34) Recent studies have suggested that even though a vigorous CTL response is generated in secondary lymphoid organs, the ability of these T cells to accumulate at the site of tumor growth is crucial, and IFN-g has been shown to induce the secretion of chemokines including IP-10, Mig, and I-TAC, which play important roles in regulating the migration of tumor-specific T cells to the tumor site. 46, 47) Most importantly, tumor regression is not the result of the number of infiltrating cells but the activation status of these lymphocytes, and these crucial events can be modulated by IFN-g. 48) Alternatively, IFN-g can also up-regulate the expression of HLA class I antigen and antigen processing machinery (APM) components, including the peptide transporter subunits TAP1 and TAP2, the immunoproteasome subunits LMP2 and LMP10, and the endoplasmic reticulumresident chaperone tapasin. These molecules are often shown to be very low expressed in HPV-associated human tumors, thereby resulting in impairing T cell response. 9, 49) In fact, down-regulation of TAP1, TAP2 and HLA were observed in the EC9706 cancer cell line and the expression levels of these molecules were up-regulated by IFN-g (our unpublished data). Therefore, the enhanced expression of IFN-g in the tumors from vaccinated-mice might not only promote antigen presentation in the E7-containing cancer cells but also infiltration of activated lymphocytes into the tumor site, which restore the anti-tumor immune responses.
It is well been knomn that granzyme B and perforin are two downstream factors for CD8
ϩ T-cell function during the effector phase of the CTL response. 34) In this regard, up-regulation of granzyme B, perforin and TNF-a in the tumor tissues from vaccinated-mice indicated that the tumor-infiltrating lymphocyes in the tumor microenvironment were efficiently activated by the fusion protein vaccine, and these tumor-specific CTLs might kill tumor cells in a cell contactdependent fashion that is likely mediated by perforingranzyme B pathway or the classical apoptotic receptor pathway in which TNF-a play an important role. Because several members of the caspase family were confirmed to be activated by granzyme B or TNF-a in vitro. 34, 50) Therefore, we believed that the HPV16 mE6D/mE7/TBhsp70D protein vaccine could modulate the tumor microenvironment by enhancing the expression of immune mediators, which in turn stimulate the expressing of lymphokines or chemokines in the tumor site that could shift the balance of the immune system and cancer in favor of the host against E7-expressing malignant cells. We are currently investigating the therapeutic efficacy of the HPV16 mE6D/mE7/TBhsp70D vaccine against HPV16 E7-expressing human ESCC, and elucidating the possible roles of perforin and granzyme B in the target cell killing to further address the detail pathways involved in the CTL-induced apoptosis using the Hu-PBL-SCID mouse model system.
In summary, we have established a Hu-PBL-SCID mouse model for the evaluation of ESCC cancer vaccine, and firstly reported the efficacy of the vaccine against HPV16 E7-expressing human esophageal carcinoma using this model. Our study demonstrated that a recombinant adjuvant-free fusion protein vaccine is superior to inducing specific cellular immune responses, resulting in the inhibition of HPV16 E7-expressing ESCC tumor growth in the in vivo model. These data provide a scientific basis for esophageal carcinoma active immunotherapy and offer the evidence of therapeutic vaccines for HPVs-related cancer in the future studie.
